Local delivery of SN-38 using a biodegradable implantable membrane for treatment of glioblastoma.

Le résumé fourni par la source

e14100 Background: Glioblastoma (GBM) remains a lethal disease with high rates of local recurrence despite maximal surgical resection and standard chemoradiotherapy. Systemic delivery of cytotoxic agents is limited by the blood–brain barrier and dose-limiting toxicity. CEB-01 is a biodegradable nanofiber membrane designed for local delivery of SN-38, a potent topoisomerase I inhibitor, directly to the surgical cavity. This study evaluated the preclinical efficacy, potency, and local tolerability of CEB-01 in GBM models. Methods: The antitumor activity of SN-38 was assessed in glioblastoma cell lines, including temozolomide-resistant and MGMT-positive and -negative models (GBM cell line panel Sanger Institute). In vivo efficacy and local tolerability of CEB-01 were evaluated in rodent intracranial models following surgical implantation in the brain. Tumor growth, histopathology, and neurological tolerance were assessed. External preclinical data were used to contextualize local SN-38 dose ranges and exposure relative to previously reported delivery strategies. Results: SN-38 demonstrated markedly higher in vitro potency compared with temozolomide and carmustine, with IC50 values approximately 1,000-fold lower across GBM cell lines and preserved activity in MGMT-positive and temozolomide-resistant models. In vivo implantation of CEB-01 showed good local tolerability, with no significant behavioral toxicity, weight loss, or fibrosis observed during long-term follow-up. Histological evaluation revealed only localized cortical changes related to surgery and implantation, comparable to incision controls. Dose-scaling analyses indicated that local SN-38 delivery in the low milligram range is pharmacologically plausible while minimizing systemic exposure, supporting further translational development. Conclusions: These preclinical data support CEB-01 as a promising local drug-delivery strategy for glioblastoma, combining high antitumor potency of SN-38 with acceptable local tolerability. Localized sustained delivery of SN-38 may overcome key limitations of systemic chemotherapy in GBM and warrants further translational and clinical investigation.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.